ArticleFrontiers in pharmacology2025
Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Previous randomized controlled trials have shown good efficacy and safety of omadacycline in patients with infectious diseases, but relevant real-world evidence is still insufficient. This large-scale study aimed to explore the efficacy and safety of omadacycline for the treatment of infectious diseases in real-world conditions. Methods: This was a retrospective, real-world study. A total of 2587 patients with infectious diseases who received omadacycline treatment were enrolled. Clinical success was defined as resolution or significant improvement of infection-related signs and symptoms without the need for salvage antimicrobial therapy. Results: After omadacycline treatment, 81.6% of patients achieved clinical success. Multivariate logistic regression analysis suggested that older age [odds ratio (OR): 0.991, Conclusion: Omadacycline possesses favorable efficacy and safety for the treatment of infectious diseases. Baseline age, malignancy history, renal function, mechanical ventilation, ICU, LOS, and omadacycline use duration are strong predictors of clinical success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.